Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study-Reference-Cited by-同舟云学术

Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study

Published:2019-04-03 Issue:2 Volume:26 Page:66-73
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Shen Kai-Ni¹,Zhang Cong-Li¹,Tian Zhuang²,Feng Jun¹,Wang Yi-Ning³,Sun Jian⁴,Zhang Lu¹,Cao Xin-Xin¹,Zhou Dao-bin¹,Li Jian¹

Affiliation:

1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China;

2. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China;

3. Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China;

4. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China

Funder

National Nature Science Foundation of China

Beijing Municipal Science & Technology Commission

Peking Union Medical College New Star

Publisher

Informa UK Limited

Subject

Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2019.1594759

Reference27 articles.

1. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment